Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NetEase
NTES
|
+$832M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$464M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$463M |
| 4 |
LendingTree
TREE
|
+$100M |
| 5 |
MarketAxess Holdings
MKTX
|
+$98.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPLK
Splunk Inc
SPLK
|
+$429M |
| 2 |
CarMax
KMX
|
+$361M |
| 3 |
Colgate-Palmolive
CL
|
+$347M |
| 4 |
Meta Platforms (Facebook)
META
|
+$266M |
| 5 |
AMTD
TD Ameritrade Holding Corp
AMTD
|
+$263M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 35.81% |
| 2 | Communication Services | 18.65% |
| 3 | Healthcare | 14.84% |
| 4 | Financials | 8.89% |
| 5 | Technology | 8.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PHD
151
DELISTED
Pioneer Floating Rate Fund
PHD
| $14.2M | 0.02% |
1,236,803
| – | – |
|
152
WEC Energy
WEC
$35.7B
| $13.6M | 0.02% |
204,107
-2,430
| -1% | -$163K |
|
|
SPLK
153
DELISTED
Splunk Inc
SPLK
| $13.2M | 0.02% |
159,481
-5,845,957
| -97% | -$429M |
|
|
VAR
154
DELISTED
Varian Medical Systems, Inc.
VAR
| $13M | 0.02% |
117,375
| – | – |
|
|
ADAP
155
DELISTED
Adaptimmune Therapeutics
ADAP
| $12.8M | 0.02% |
1,920,593
+541,289
| +39% | +$4.18M |
|
|
NSL
156
DELISTED
NUVEEN SENIOR INCM FD
NSL
| $12.5M | 0.02% |
1,915,000
| – | – |
|
157
Edison International
EIX
$28.2B
| $12.4M | 0.02% |
196,460
-67,220
| -25% | -$5.13M |
|
|
EVF
158
Eaton Vance Senior Income Trust
EVF
$90.1M
| $12.3M | 0.02% |
1,885,000
| – | – |
|
159
STAAR Surgical
STAA
$1.21B
| $12.3M | 0.02% |
792,407
+93,665
| +13% | +$1.39M |
|
160
NovoCure
NVCR
$1.73B
| $12.2M | 0.02% |
+604,117
| New | +$11.6M |
|
161
Teladoc Health
TDOC
$1.22B
| $12.1M | 0.02% |
347,925
+41,913
| +14% | +$1.39M |
|
|
FARO
162
DELISTED
Faro Technologies
FARO
| $11.9M | 0.01% |
253,020
+24,616
| +11% | +$1.15M |
|
163
Digimarc Corp
DMRC
$147M
| $11.6M | 0.01% |
319,873
+58,411
| +22% | +$2.12M |
|
164
Ambarella
AMBA
$3.77B
| $11.5M | 0.01% |
196,537
+19,538
| +11% | +$1.09M |
|
165
PG&E
PCG
$38.3B
| $10.8M | 0.01% |
241,899
-69,080
| -22% | -$3.87M |
|
166
Lindblad Expeditions
LIND
$1.94B
| $10.5M | 0.01% |
+1,072,701
| New | +$11.1M |
|
167
Weibo
WB
$2B
| $10.2M | 0.01% |
98,133
-3,905
| -4% | -$404K |
|
|
AFT
168
DELISTED
Apollo Senior Floating Rate Fund Inc.
AFT
| $10M | 0.01% |
617,746
| – | – |
|
169
CEVA Inc
CEVA
$910M
| $9.94M | 0.01% |
215,389
+22,191
| +11% | +$1.02M |
|
170
Stratasys
SSYS
$679M
| $9.19M | 0.01% |
460,537
+57,032
| +14% | +$1.24M |
|
|
MB
171
DELISTED
MINDBODY, Inc. Class A Common Stock
MB
| $9.14M | 0.01% |
300,131
+33,867
| +13% | +$1.04M |
|
|
ONC
172
BeOne Medicines Ltd
ONC
$32.8B
| $8.53M | 0.01% |
87,251
+7,241
| +9% | +$663K |
|
173
British American Tobacco
BTI
$131B
| $8.29M | 0.01% |
123,795
-63,753
| -34% | -$4.16M |
|
174
HUTCHMED
HCM
$1.93B
| $8.14M | 0.01% |
206,454
+20,850
| +11% | +$666K |
|
175
SLB Ltd
SLB
$73.6B
| $8.03M | 0.01% |
119,127
| – | – |
|
Similar funds
Baillie Gifford & Co's Q4 2017 Portfolio in Review
As of Q4 2017, Baillie Gifford & Co held 210 positions worth $80.4B, up 1.8% from $79B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Baillie Gifford & Co's Q4 2017 filing shows 12 new, 75 increased, 93 reduced and 9 closed positions. Its largest new stake was Thermo Fisher Scientific: 2,423,018 shares worth $460M. The largest sale was Splunk Inc, an estimated $429M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 36% of assets, down from 37% a quarter earlier, followed by Communication Services and Healthcare.
- Baillie Gifford & Co's largest Q4 2017 buy was Thermo Fisher Scientific: 2,423,018 shares worth $460M.
- Baillie Gifford & Co added most to NetEase in Q4 2017, an estimated $832M increase.
- Baillie Gifford & Co's biggest Q4 2017 reduction was Splunk Inc, cutting an estimated $429M.
- Baillie Gifford & Co fully exited Colgate-Palmolive in Q4 2017, selling an estimated $347M.
- Baillie Gifford & Co's ten largest holdings make up 51% of its $80.4B portfolio in Q4 2017.
- Baillie Gifford & Co opened 12 new positions and closed 9 in Q4 2017.
- Baillie Gifford & Co's portfolio value rose 1.8% quarter-over-quarter to $80.4B.
Based on Baillie Gifford & Co's 13F filing for Q4 2017, filed 13 Feb 2018.